Peer-reviewed veterinary case report
Choice of Tactics for Experimental Therapy of Chronic Heart Failure with ALM-802 Compound.
- Journal:
- Bulletin of experimental biology and medicine
- Year:
- 2021
- Authors:
- Barchukov, V V et al.
- Affiliation:
- V. V. Zakusov Research Institute of Pharmacology
- Species:
- rodent
Abstract
The cardioprotective activity of ALM-802 compound was demonstrated in model experiments simulating postinfarction chronic heart failure in rats forming in 90 days after anterior transmural myocardial infarction. ALM-802 decreased the left ventricle and improved its inotropic function (p=0.038). This effect was observed in case of systematic administration of ALM-802 over 28 days (starting from day 91 after infarction modeling). This is apparently the minimum time for the cardioprotective effect of ALM-802 to prevent or treat the resulting heart failure, because short-term systematic therapy (15 days) produced no positive effect.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/33893957/